Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients

Joel M. Michalski, Elizabeth R. Lyden, Andrea J. Lee, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)1989-1995
Number of pages7
JournalFuture Oncology
Volume15
Issue number17
DOIs
StatePublished - Jun 2019

Keywords

  • 10-day decitabine
  • acute myeloid leukemia
  • frail patients
  • hypomethylating agents
  • older adults
  • overall survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients'. Together they form a unique fingerprint.

  • Cite this